Global assembling of Academicians, Researchers, Scholars & Industry to disseminate and exchange information at 100+ Allied Academics Conferences
Biochemical processes in the central nervous system (CNS) are hard to investigate, due to the unavailability of samples from the CNS in the in vivo investigations. There are only a few direct methods that enable us to determine the biochemical processes in the human brain during its life span. Today, basic studies in the field of radiochemistry have been found in the investigation of the biochemical processes in the CNS. Mirko Diksic is a scientist who has successfully used his abundant experience in basic sciences and applied that knowledge to neurobiological and neuropharmacological research. His work has been cited in more than 7000 scientific articles and papers around the world. He has been a guest of numerous international institutions and scientific meetings, has travelled around the world and has been a guest lecturer over 100 times. After joining the Montreal Neurological Institute in 1979 Mirko Diksic, along with a research group, devised and set up the first medical cyclotron facility in Canada designed exclusively for medical research. The cyclotron was opened in 1981, and was used very successfully for research until 1991, when it was replaced with a new and improved machine still used today. He made a substantial contribution to the development of the methods for the synthesis of radioactive labeled compounds used medical research. At the same time, Mirko Diksic established a radiochemical laboratory to prepare biologically active molecules marked with the short living 18F md 11C radioisotopes. These labeled molecules have been used in investigations of processes in the human CNS in vivo using PET. Mirko Diksic made a significant contribution to oncological brain research. Soon after the installation of the cyclotron, one of the first radioactively labeled radiopharmaceuticals was a drug named Carmustine (1,3 di-chloroethylen nitrosourea, BCNU), that is often used in the treatment of brain tumors. Mirko Diksic was the first person to demonstrate that the effects of BCNU depend on its routes of administration. Using PET studies, it was determined that 11C-BCNU following intra-arterial administration accumulated in brain tumors 50% more than after intravenous administration.